Shares

16 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2023

Aug 14, 2023

SELL
$11.39 - $13.72 $252,903 - $304,638
-22,204 Reduced 28.88%
54,668 $695,000
Q1 2023

May 15, 2023

SELL
$10.73 - $13.6 $418,867 - $530,903
-39,037 Reduced 33.68%
76,872 $864,000
Q4 2022

Feb 14, 2023

BUY
$11.8 - $13.78 $387,146 - $452,108
32,809 Added 39.48%
115,909 $1.54 Million
Q4 2020

Feb 16, 2021

SELL
$9.33 - $12.48 $526,212 - $703,872
-56,400 Reduced 40.43%
83,100 $1.03 Million
Q3 2020

Oct 26, 2020

SELL
$10.33 - $14.49 $468,982 - $657,846
-45,400 Reduced 24.55%
139,500 $1.46 Million
Q2 2020

Aug 11, 2020

BUY
$11.49 - $15.26 $472,239 - $627,186
41,100 Added 28.58%
184,900 $2.59 Million
Q1 2020

May 08, 2020

BUY
$8.11 - $15.23 $360,895 - $677,735
44,500 Added 44.81%
143,800 $1.69 Million
Q4 2019

Feb 14, 2020

SELL
$10.28 - $14.38 $133,640 - $186,940
-13,000 Reduced 11.58%
99,300 $1.41 Million
Q3 2019

Oct 23, 2019

SELL
$10.05 - $14.55 $504,510 - $730,410
-50,200 Reduced 30.89%
112,300 $1.18 Million
Q2 2019

Aug 14, 2019

BUY
$13.1 - $14.95 $186,020 - $212,290
14,200 Added 9.58%
162,500 $2.37 Million
Q4 2018

Feb 14, 2019

BUY
$13.96 - $18.26 $633,784 - $829,004
45,400 Added 44.12%
148,300 $2.59 Million
Q3 2018

Nov 16, 2018

BUY
$13.63 - $15.7 $1.12 Million - $1.29 Million
82,200 Added 397.1%
102,900 $1.57 Million
Q2 2018

Aug 15, 2018

SELL
$13.44 - $17.59 $662,592 - $867,187
-49,300 Reduced 70.43%
20,700 $286,000
Q1 2018

May 16, 2018

SELL
$13.8 - $16.99 $3.59 Million - $4.43 Million
-260,500 Reduced 78.82%
70,000 $1.17 Million
Q4 2017

Feb 15, 2018

BUY
$11.73 - $14.75 $303,807 - $382,025
25,900 Added 8.5%
330,500 $4.69 Million
Q3 2017

Nov 14, 2017

BUY
$12.06 - $14.12 $3.67 Million - $4.3 Million
304,600
304,600 $4.3 Million

Others Institutions Holding INVA

About Innoviva, Inc.


  • Ticker INVA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 69,706,000
  • Market Cap $1.33B
  • Description
  • Innoviva, Inc. engages in the development and commercialization of pharmaceuticals in the United States and internationally. Its products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a ...
More about INVA
Track This Portfolio

Track Alberta Investment Management Corp Portfolio

Follow Alberta Investment Management Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Alberta Investment Management Corp, based on Form 13F filings with the SEC.

News

Stay updated on Alberta Investment Management Corp with notifications on news.